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Abstract
Purpose The study aims to contrast the efficacy of
trophectoderm biopsy preimplantation genetic screening
(PGS)/vitrification (VTF)-all cycles to past treatment proto-
cols. Specifically, do these applied technologies increase live
birth rates on a per cycle/first transfer basis?
Materials and methods An observational, retrospective co-
hort study of first transfer outcomes was performed in two
groups. Group 1 (PGS) included PGS/VTF-all cycles, and
group 2 (no PGS) included the first transfer from non-PGS
fresh cycles or VTF-ALL cycles. In group 1, all blastocysts
were biopsied on days 5/6, vitrified and array CGH per-
formed. Group 2 patients had embryo transfers on day 3 or
day 5. All blastocysts were vitrified and warmed according to
μS-VTF protocols. Clinical pregnancies and implantation
were confirmed by ultrasound and live birth information
attained. Results were stratified by age with donor cycles ex-
cluded, and to eliminate bias, the same groups were then
validated on a per cycle basis. Chi-squared used to determine
significance.
Results Analyzing 287 embryo transfers and 1,000+ PGS-
tested blastocysts, an overall 97 % increase in live births fa-
vored group 1 (PGS). When utilizing PGS/VTF-ALL cycles,
patients under 43 years old exhibited higher implantation,
clinical pregnancy, and ongoing/live birth rates. Re-
analyzing the data to include all cycles initiated revealed
higher live birth rates in group 1 age groups ≤34 and 38–
40 years old.
Conclusion Validating PGS on a per cycle basis eliminated
data bias by including patients without blastocysts to biopsy
or euploid embryos. Clearly, PGS uses blastocysts more effi-
ciently to achieve success, while many women over 40 may
benefit most by understanding why some failures occur.
Support None
Keywords Blastocyst . Biopsy . PGS . Validation .
Trophectoderm
Introduction
A healthy baby is the end goal for patients choosing assisted
reproduction technologies (ART; [1]). The potential or percent
chance for achieving a live birth often guides the patients’
decision process for treatment. Success is generally evaluated
by clinical pregnancies, live births, and implantation efficien-
cy. These outcomes are influenced by cycle initiation, ovarian
stimulation, oocyte quality, embryo culture, and transfer se-
lections [2], as well as patient age. Therefore, comparisons
among different clinics are difficult to assess and potentially
misleading [3]. Fundamentally, it is an individual clinics’ re-
sponsibility to institute a comprehensive quality management
program for self-evaluating and verifying their efficacy of
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procedural success, especially when applying new technolo-
gies. Furthermore, it is particularly beneficial to report and
evaluate a patient’s end goal in terms of singleton live births,
the best determinant of treatment success [1].
To accurately assess pregnancy outcomes, one must under-
stand the intricacy required to achieve a pregnancy via in vitro
fertilization (IVF). Even when laboratory procedures are opti-
mized, success is highly dependent on proper embryo selection
for transfer [4]. Embryo selection is imperative for improved
pregnancy rates, but is subject to variable technician and
program-specific criteria [5]. Subjective morphology grading
[4] has been a widely accepted and reliable standard to judge
embryo quality. The international movement toward single em-
bryo transfers (SET) has increased the pressure to improve
embryo selection criteria [6]. Yet, our ability to more accurately
choose embryos with a high probability for success has proven
difficult utilizing morphologic assessments alone [7].
Our clinic experienced a fundamental shift in treatment ide-
ology in 2012 when we moved from a standard fresh blastocyst
transfer treatment regime (strictly utilizing the American
Society for Reproductive Medicine (ASRM) guidelines) to
the application of day 5/6 blastocyst biopsy with vitrification-
all cycles. Preimplantation genetic screening (PGS) ploidy
determination was followed by subsequent euploid vitrified-
warmed embryo transfer emphasizing single embryo transfer.
The rapid inclusion of blastocyst biopsy in ART, in conjunction
with PGS and vitrification-all cycles in our clinic, prompted us
to question if our overall success had improved. This change in
treatment plan potentially created a selection bias, resulting in
an increase in pregnancies per transfer by eliminating patients
failing to produce a normal blastocyst. To fully validate the
advantages of blastocyst biopsy with PGS, we sought to nor-
malize and contrast pregnancy outcomes of non-PGS and PGS
cycles over an 18-month duration before and after, respectively,
our inclusion of established blastocyst biopsying procedures.
Materials and methods
Study design
Using an observational retrospective cohort analysis, we
strived to evaluate the efficacy of our blastocyst biopsy pro-
gram. Prior to July 2012, PGS cycles accounted for <20 % of
all cycles initiated in our clinic. With the rapid inclusion of
blastocyst biopsy beginning in January 2012, by July 2012,
PGS aneuploidy screening accounted for over 90 % of all ini-
tiated cycles in our clinic. This study aimed to evaluate the shift
from utilizing morphological quality grading only for fresh
embryo transfer selection to morphology combined with genet-
ic analysis for vitrified warmed embryo transfer cycles.
Two study arms were evaluated, the first was per transfer,
and standard implantation analysis and live birth per transfer
were analyzed. A transfer must have been attempted for inclu-
sion in this analysis. Since many cycles fail to attain a euploid
blastocyst for transfer, the traditional measures used to evalu-
ate live birth per transfer are inherently biased. The second
arm was per cycle, and all cycles that received stimulation
were included. This validation approach aimed to eliminate
fundamental inaccuracies when comparing PGS tested em-
bryo transfer data to untested embryo transfer cycles.
In an effort to further reduce bias, only the patients’ first
transfer attempt was used for comparisons. If a cycle whose
intended transfer did not result in a transfer, the outcome was
classified as not pregnant and included for statistical analysis
in the per cycle arm. The study was IRB approved for retro-
spective analyses.
Cohort determination
All cycles included in this study were initiated from January
2011 to December 2013. All cycles initiated from July 2012
through December 2013 were included in group 1 (PGS). Of
all these cycles, only those that met the exclusion criteria were
excluded. All patients enrolled in group 1 (PGS) initiated a cycle
intending the use of PGS and transfer of only euploid blastocysts.
All cycles initiated from January 2011 through June 2012
were included in group 2 (no PGS), and all cycles meeting
exclusion criteria were excluded. The decision to separate two
cohorts during this time period was justified to eliminate a
population bias, as all cycles after July 2012 were encouraged
to utilize blastocyst biopsywith a significant reduction in fresh
ET occurring. Population analysis was performed to identify
differences between the two groups.
Population parameters
Inclusion criteria
All cycles performed standard IVF stimulation protocols,
established embryo culture practices, intracytoplasmic sperm
injection (ICSI), day 5 or 6 biopsy (group 1), and microSecure
vitrification [8, 9] of all fair to excellent quality blastocysts
(i.e., ≥3BB) (group 1 and group 2—cryo-all). All cycles, in-
cluding canceled cycles, were used in the per cycle analyses.
Group 1 (PGS) and group 2 (no PGS) patients used autol-
ogous oocytes, performed standard IVF/ICSI cycles, and mor-
phology dictated transfer selection for group 2 (no-PGS) and
morphology with a euploid genetic result dictated group 1
(PGS) transfer selection, unless gender was requested.
Inclusion criteria for the per cycle and per transfer analysis
arms are displayed in a flow chart (Fig. 1). There were no
cycles in group 1 (PGS) that chose to transfer untested embry-
os. Likewise, every cycle initiated after June 2012 grew all
embryos to the blastocyst stage for biopsy. Every cycle includ-
ed in group 1 (PGS) intended and continued for PGS
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regardless of any embryology or patient factors. If no blasto-
cysts resulted, all embryos were discarded, and the cycle was
classified as not pregnant.
Cycle intentions were made at the start of controlled ovar-
ian hyperstimulation and any cycle which received medica-
tion, but was canceled for any reason, was included as a neg-
ative result in the per cycle arm. One cycle in group 2 was
converted to an intrauterine insemination (IUI) and included
in the per cycle analysis as a negative, as the IUI did not result
in pregnancy. Every attempt was made to include cycles dur-
ing the designated time periods, and every cycle which initi-
ated for transfer was included.
Exclusion criteria
Both group 1 (PGS) and group 2 (no PGS) were designed to
reflect a patients’ intention for transfer, thus no embryo or
oocyte banking cycles were used for calculations in either
group (Fig. 1). If a patient’s egg retrieval occurred in the des-
ignated time frames, but no resulting embryos were trans-
ferred due to spontaneous natural pregnancy following treat-
ment (n = 3), their cycle was excluded from their respective
group and termed banking. All single gene diagnosis cycles
and/or oocyte cryopreservation cycles were excluded. All
PGS cases that initiated during the group 2 (no PGS) time
frame were excluded. There were no exclusions for any
embryology, patient, or cycle parameters, with every cycle
that initiated for transfer being included.
Embryo culture, grading, biopsy, and PGS testing
Using MCO-5 M mini Sanyo/Panasonic tri-gas incubators
(5 % 02/5.3–6.0 % CO2), we group cultured up to five embry-
os per 25 μL droplet of Global™ medium (LG; Life Global,
Guilford, CT) supplemented with 7.5 % synthetic protein sup-
plement under Ovoil™ (Vitrolife, Englewood, CO) until blas-
tocyst biopsy [10]. All oocytes retrieved were evaluated for
maturity and had ICSI performed 2–6 h post-egg retrieval [9].
Embryos were initially evaluated on day 3; laser zona dissec-
tion was performed using a 1480-nm diode laser (Zilos-tk™;
Hamilton Thorne, Beverly, MA), and embryo incubation con-
tinued until day 5/6 evaluations [10]. The zona opening cre-
ated on day 3 allowed trophectoderm (TE) to prematurely
rupture through a 10–12-μm furrow in the zona. The same
laser was used on day 5/6 for biopsying using a combination
of laser pulses and mechanical separation to achieve 3–10 TE
cells [10] used for array CGH (Genesis Genetics, Plymouth,
MI). Blastocysts were graded at biopsy using a modified
Gardner scale [11]. The modification was to account for pre-
mature hatching: grade 3 = 5–10 % TE extrusion (full blasto-
cyst), grade 4 = 10 %–50 % TE extrusion (expanded blasto-
cyst), and grade 5 ≥ 50 % TE extrusion (hatching blastocyst).
Inner cell mass (ICM) and TE were independently graded
Flow Chart: Patient Enrollment and Group Determination
Autologous Cycles Initiated  January 2011-December 2013 
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Fig. 1 Experimental flow
diagram indicating patient
enrollment and treatment group
determination assignments,
revealing the total number of
patients included or excluded
from the study
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from top quality BA^ to fair quality BB^ and poor quality BC^
with the first letter in the grade assigned to the ICM and the
second to TE. A grade of 3BB or better was required to initiate
biopsy, and all embryos were allowed to culture to day 6 for
further expansion to meet biopsy criteria.
Vitrification and embryo transfer
Fair to excellent quality blastocysts (≥3BB grade) were vitrified
on day 5 or day 6 using microSecure-VTF in non-DMSO vit-
rification (VTF) solutions (Innovative Cryo Enterprises,
Linden, NJ; 9). Aseptic microSecure VTFwas performed using
a 3-step dilution (5 min/5 min/1 min); individual blastocysts
were loaded into 300 μm ID flexipettes (Cook Medical,
Spencer, IL; 3 μl volume); flexipettes were then dried and
inserted tip first into prelabeled 0.3 ml CBS™ embryo straws;
the straw weld sealed and plunged directly into LN2 [8]. Rapid
warming was achieved by direct placement of the vitrified
flexipettes into a 37 °C 0.5 M sucrose bath [9]. Within 10 s,
each blastocyst was pipette directly from the flexipette into an
open 200 μl droplet of 1.0 M sucrose solution and then trans-
ferred into 100 μl droplets under oil for 3 min intervals.
Embryos were serially diluted in declining sucrose solutions
(T1–T4), before isotonic equilibration in Hepes-LG medium.
Warmed blastocysts were then cultured in LG medium + pro-
tein for 1–3 h prior to vitrified ET (VFET).
All VFET cycles were hormone replacement cycles using
oral estradiol, estradiol patches, or intramuscular (i.m.) estra-
diol valerate followed by i.m. progesterone in oil.
Progesterone in oil was started when endometrial thickness
was >8 mm after documentation of serum progesterone level
of <1.0 ng/ml. VFETwas performed after 5 days of intramus-
cular progesterone administration. All transvaginal ultrasound
guidance ET procedures were performed by a single physi-
cian. Pregnancies were initially tested 10 days post-ET and
implantation subsequently assessed by transvaginal ultra-
sound beginning 4 weeks later. Live births were confirmed
by written or oral communication with patients.
Statistical analysis
Initial comparisons for implantation, clinical pregnancies, live
births, and spontaneous abortions were calculated per first
transfer attempt. This analysis was the per transfer arm of
Table 2 Per transfer arm: transfer comparisons
Group 1 (PGS) Group 2 (no PGS)
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Table 1 Population comparison
of patients in Group 1 versus
Group 2
Mean age % Antagon % Agonist Mean # follicle Mean FSH
Age ≤ 34 NS
31.6 vs 31.5
NS
63 vs. 67 %
NS
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Statistical significance determined by t test calculations; NS not significant p > 0.05
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the study and included only cycles that resulted in a transfer.
To eliminate study bias, all comparisons between groups was
performed on a per cycle initiation to outcome basis. This
second analysis was the per cycle arm of the study and includ-
ed all cycle stimulation starts. The per cycle analysis included
the per transfer data, all canceled cycles, cycles that did not
produce any embryos, and/or cycles where all embryos were
aneuploid. This analysis was used to compare the groups with
stimulation start as the denominator. Student’s t test was used
to assess the significance of potential patient population dif-
ferences between group 1 and group 2 traits (e.g., average age,
stimulation protocol, average follicle count, and day 3 FSH).
Alternatively, chi-squared analyses were performed to con-
trast differences in pregnancy outcomes (e.g., clinical preg-
nancy, implantation, and live birth rates).
Results
Population comparisons were conducted between group 1 and
group 2 to assess variations in patient parameters (Table 1).
No differences in age, stimulation protocol, or antral follicle
count were revealed; however, day 3 FSH levels were higher
(p < 0.05) in group 2 (no PGS) women in the 35–37 and ≥43
age groups. Group 1 (PGS) achieved higher (p < 0.05)
implantation and clinical pregnancy rates when sorting by
age groups under 43 (Table 2). Live birth rates were statisti-
cally higher for age groups <34, 38–40, and 41–42-year-old
women receiving single euploid ET. Re-analyzing the data to
include all cycles regardless of outcome per first transfer
showed significance for age groups ≤34 and 38–40
(Table 3). Utilizing the 2013 CDC/SART averages for live
birth per cycle, we contrasted them to group 1 (PGS) and
group 2 (no PGS) live birth outcomes (Fig. 2). An increase
in average pregnancies was observed in each age group with a
97 % increase in average live birth rates favoring group 1
(PGS). Additionally, fewer (p < 0.01) embryos were trans-
ferred in group 1 (PGS) patients under 43 years old
(Table 4), whom also had a lower overall spontaneous abor-
tion (SAB) rate (p < 0.05; Table 5). Thus, the overall efficacy
of pregnancy establishment/success was greater in group 1
(PGS).
Discussion
This study aimed to determine the efficacy of a progressive
treatment change utilizing blastocyst biopsy with PGS and
perform a detailed, unbiased self-assessment. The results gen-
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Fig. 2 Live birth rates per cycle
starts were compared between
group 1 and group 2. The benefit
of transferring ploidy screened
embryos in group 1 is contrasted
to both untested embryo transfers
within a single clinic (group 2)
and to the 2013 SART national
live birth averages. Group 1
clearly displays an increase in live
births which reinforces the
benefits gained by the routine IVF
commitment to the clinical
application of PGS
Table 3 Per cycle arm:
the comparative effect of
implementing blastocyst
biopsy/PGS on a per
cycle start basis
Group 1 (PGS) Group 2 (no PGS)
Age # cycles # ET # live birth Live birth/cycle # cycles # ET # live birth p value
≤34 46 43 35 76.1 % *46.2 % 65 64 30 *p = ≤0.01
35–37 43 41 30 69.8 % 48.6 % 35 32 17 p = 0.07
38–40 47 37 30 63.8 % *27.8 % 36 35 10 *p = ≤0.01
41–42 28 12 8 28.6 % 6.3 % 16 15 1 p = 0.124
43+ 8 1 1 12.5 % 0.0 % 8 7 0 p = 1.0
*Differences in live birth rate were determined by chi-squared analysis
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SAB results and the lack of abnormalities being reported
among newborns. These findings confirm the belief that blas-
tocysts are the ideal stage for biopsy intervention [12] and that
PGS, in conjunction with vitrified warmed embryo transfers,
is an ideal option to efficiently succeed in transferring a single
embryo. The overall analysis of clinical pregnancy per first
transfer was higher for women <43 years using the PGS/VTF
treatment protocol (group 1). Most importantly, implantation
for all age groups improved (p < 0.05) in group 1 (PGS), re-
vealing better embryo utilization, strengthening our decision
to move to elective single embryo transfers as our standard of
care.
Ultimately, our study objective was to determine whether a
blastocyst biopsy/vitrification program benefits all patients on
a per cycle analysis basis. Our results not only showed an
increase in pregnancies in all age groups when analyzing per
cycle start, but it also effectively reduced miscarriage rates per
transfer. In turn, our overall take home baby rate did increase
97 % per first transfer attempt. Not surprisingly, the per cycle
analysis for the live birth rates was not different for patients
over 4 years old. However, our failure to achieve significance
at p < 0.05 for women in the 35–37 year age group was un-
fortunately traced back to a single group 1 (PGS) patients’
elective termination (i.e., abortion), not due to chromosomal
abnormalities or pregnancy failure. Nonetheless, we feel the
ability to diagnose potential cycle failures and drastically re-
duce the rate of pregnancy losses (i.e., SAB) strongly justifies
the intervention needed to biopsy a blastocyst. Additionally,
the ability to effectively control and reduce potential multiple
births, to less than 2 %, in good prognosis patients through the
routine usage of a single euploid embryo encourages the ap-
plication of PGS to maintain a high standard of patient care.
The transferring of euploid blastocysts within this study sup-
ports the importance of ploidy screening for increasing im-
plantation, and ultimately, live birth success.
It is noteworthy to recognize that our comparisons were not
run simultaneously as a randomized controlled PGS trial.
Indeed, dramatically different time frames were evaluated as
the clinic did not offer PGS to all patients in 2011, and bymid-
2012, all cycles initiated were intended for and subsequently
underwent PGS testing. The groups were evaluated for base-
line differences, and no capital improvements or significant
changes to patient care or laboratory protocols were imple-
mented during the time frames in question other than blasto-
cyst biopsy. Scott and coworkers have previously shown im-
provements implementing trophectoderm biopsy within a ran-
domized controlled trial (RCT, [13]), complementing the re-
sults found in this analysis. Zhu and coworkers first reported
the general advantages of vitrification-all cycles improving
pregnancy outcomes [14]. Although we clearly found this to
be true early on for PGS cycles compared to delayed fresh ET
on day 6 (unpublished data), this study did not specifically
compare PGS/FET to FETwithout PGS. However, the empir-
ical data generated in our VTF validation analyses [9] did
support the concept that our VFET cycles were equal to or
better than fresh ET. Finally, some patient parameters (e.g.,
physical characteristics, stimulation factors) were not evaluat-
ed between groups, as many parameters were not collected for
all cycles and ultimately not evaluated in this study.
Fundamentally, this study was a validation verification
intended to eliminate the bias generated through accounting
for and transferring only euploid embryos, thus allowing for a
fair, standardized analysis of live births per cycle initiation.
Our clinic’s goal to develop and optimize a path for single
embryo transfer as a standard practice was in-line with an
international movement toward decreasing multiple births as-
sociated with ART treatments. By comparing the transfer of
euploid screened embryos to previously unscreened fresh or
frozen transfer cycles, our normalized data clearly showed
significant improvements in live birth outcomes.
This observational study was our best attempt to self-
evaluate and validate a change in patient care. It is well un-
derstood that this was neither a prospective nor randomized
study, but it has generated relevant data which supports other
RCTs regarding the efficacy of blastocyst biopsy with aneu-
ploidy screening. Our study also chose to only calculate per
first transfer. A per cohort analysis could presumably achieve
a higher live birth percentage by including all transfers for a
single patient. However, we question, when calculating per
cohort and utilizing ASRM guidelines for transfer, what in-
crease in adverse outcomes (i.e., biochemical pregnancy,
SAB, or multiple gestations) may patients endure.
Undoubtedly, PGS adds cost to the cycle, but what costs can
be placed on the emotional distress and trauma endured by
women experiencing repeated failures and fetal loss. Thus, a
true assessment of cost per live birth comparing PGS versus
untested embryo transfer has not been performed. Overall, this
study defends our current clinical practice, providing
Table 4 Average number embryos transferred
Age group Group 1 Group 2 p value*
≤34 1.2 1.9 p < 0.01
35–37 1.4 2.0 p < 0.01
38–40 1.2 2.5 p < 0.01
41–42 1.2 2.5 p < 0.01
43+ 1.0 2.7 p = 0.12
*t test used to determine significance between columns within row
Table 5 Overall spontaneous abortion rate comparisons between PGS
(group 1) and non-PGS (group 2) treatments, independent of age
Group 1 Group 2 p value
Average 4.4 % 12.9 % p ≤ 0.05
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optimism that we are offering our patients a justified, quicker,
more emotionally balanced path to pregnancy success.
Factoring in the limited pregnancy loss(es) and increased sin-
gleton live births, we are now able to offer a more enjoyable,
safer, and positive IVF experience for the majority of our
patients.
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